Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program

Olivia M. Dong, Jill Bates, Catherine Chanfreau-Coffinier, Michael Naglich, Michael J. Kelley, Laurence J. Meyer, Michael Icardi, Jason L. Vassy, Peruvemba Sriram, Craig William Heise, Salvador Rivas, Maria Ribeiro, Russell Jacobitz, Susan Rozelle, Jennifer G. Chapman, Deepak Voora

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approximately 50 sites. PHASER is staggering program initiation at sites over a 5-year period from 2019 to 2023, as opposed to simultaneous initiation at all sites, to facilitate iterative program quality improvements through Plan-Do-Study-Act cycles. Current resources in the PGx field have not focused on multisite, remote implementation of panel-based PGx testing. In addition to bringing large scale PGx testing to veterans, the PHASER program is developing a roadmap to maximize uptake and optimize the use of PGx to improve drug response outcomes.

Original languageEnglish (US)
Pages (from-to)137-144
Number of pages8
JournalPharmacogenomics
Volume22
Issue number3
DOIs
StatePublished - Feb 2021

Keywords

  • Veterans Affairs
  • clinical program
  • pharmacogenetics
  • pharmacogenomics
  • precision medicine
  • veterans

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint

Dive into the research topics of 'Veterans affairs pharmacogenomic testing for veterans (PHASER) clinical program'. Together they form a unique fingerprint.

Cite this